Your AI-Trained Oncology Knowledge Connection!
Ricardo Parrondo, MD, discusses that in treating chronic lymphocytic leukemia, BTK inhibitors like ibrutinib can pose cardiovascular risks, including hypertension; he suggests that in choosing a BTK inhibitor one should consider the patient's preexisting cardiovascular conditions.
An expert on lung cancer discusses data from TROPION-Lung05 on datopotamab deruxtecan in patients with previously treated NSCLC with actionable genomic alterations.
Joshua K. Sabari, MD, reviews the primary results from the MARIPOSA study presented at ESMO 2023 looking at amivantamab plus lazertinib in EGFR-mutated advanced NSCLC.
The panel discusses the efficacy of belantamab mafoditin and where the treatment fits in the multiple myeloma treatment landscape.
In the October edition of Snap Recap, we review the latest FDA news and the vote from the last ODAC meeting.
Joselle Cook, M.B.B.S., and Luciano Costa, MD, note promising trials investigating combination bispecific antibody therapies for patients with relapsed/refractory multiple myeloma.
Drs Luciano Costa and Binod Dhakal discuss combining bispecific antibodies with gamma secretase inhibitors for the treatment of relapsed/refractory multiple myeloma, but trials show limited benefit and added toxicity; more promising are combinations with immunomodulators like isatuximab.
Overview of challenges in managing adverse events associated with bispecific therapy in multiple myeloma, including dysgeusia, skin toxicity, and nail changes patients may experience.
Drs Cohen, Wu, and Ahn discuss HER2 in colorectal cancer, explaining that increased expression indicates possible benefit from HER2 inhibitors; Ahn summarized studies showing modest activity of dual HER2 inhibition compared to single agent trastuzumab.
Comprehensive insights on the management of adverse effects from bispecific antibodies in the treatment of multiple myeloma.
Experts share how the availability of three new bispecific therapies has transformed myeloma patient care, offering a lifeline to those previously without treatment options and showcasing positive responses in various patient populations.
Drs Wu, Ciombor, and Cohen discussed upfront molecular testing in patients with colorectal cancer to guide treatment, with Dr Ciombor reviewing HER2 testing methods and Dr Cohen noting liquid biopsy limitations.
Expert oncologists discuss dosing considerations for bispecific antibodies in the treatment of patients with multiple myeloma.
Explore significant updates in the field of EGFR-mutant lung cancer treatment, focusing on the introduction of combination therapy in the first-line setting, including the FLAURA2., MARIPOSA, and RAMOSE trials, offering improved progression-free survival and potential implications for patient care.
Sai-Hong Ou, MD, PhD, discusses the rapidly evolving landscape of first-line therapy for sensitizing EGFR mutant non-small cell lung cancer, including potential combination therapies and the introduction of new treatment options, such as antibody drug conjugates.
Insight into the importance of patient-centered care, highlighting the role of a multidisciplinary team in managing advanced renal cell carcinoma and addressing questions regarding alternative medications.
Insights into diagnosing EGFR-mutant lung cancer and explores evolving first-line treatment strategies, incorporating recent developments, combinations, and clinical trial data, while addressing challenges in testing and patient management.
Key opinion leaders reflect on treatment approaches for renal cell carcinoma in light of factors like risk classification, symptom severity, and patient preferences, with considerations ranging from active surveillance to systemic combination therapies.
Dr Sai-Hong Ou and Dr Janellen Smith discuss the case of a 59-year-old patient with non-small cell lung cancer and an EGFR mutation who experienced severe diarrhea and acne form rash while on osimertinib, providing insights into managing these treatment-related side effects.
Panelists close the discussion by offering insights and future perspectives on the treatment landscape for follicular lymphoma.
Arvind N. Dasari, MD, lead investigator of the FRESCO-2 trial, spoke about the recent approval of fruquintinib for patients with previously treated metastatic colorectal cancer.
Pooja Advani, MBBS, MD, discusses that switching from ibrutinib to second-generation BTK inhibitors like acalabrutinib leads to fewer off-target side effects like atrial fibrillation while maintaining high disease control.
Experts discuss that for patients with chronic lymphocytic leukemia intolerant to the BTK inhibitor ibrutinib, due to side effects like arthralgia, myalgia, or diarrhea, switching to a second-generation BTK inhibitor can be effective and better tolerated.
A medical oncologist discusses data from the LIBRETTO-431 clinical trial looking at first-line selpercatinib vs chemotherapy and pembrolizumab in RET fusion–positive NSCLC.
Craig Cole, MD, reviews data from DREAMM-3 on the efficacy and safety of single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma.
Sandip P. Patel, MD, reviews recent data from the PAPILLON study investigating amivantamab plus chemotherapy in the first line for patients with EGFR exon 20 insertion–mutated advanced NSCLC.
Experts on multiple myeloma discuss the clinical applications of ixazomib-lenalidomide-dexamethasone combination therapy.
Joselle Cook, M.B.B.S., discusses the RedirecTT-1 trial combining teclistamab and talquetamab for patients with relapsed/refractory multiple myeloma, noting high response rates even in high-risk myeloma but concerns about long-term resistance.
Dr Binod Dhakal discusses response rates and toxicities seen with recently approved bispecific antibodies talquetamab in patients with heavily pretreated multiple myeloma, noting high response rates even after CAR-T, but also unique side effects.
Drs Ahn and Cohen discuss the treatment of colorectal cancer, reviewing the available options and describing factors influencing treatment choice and use of maintenance therapy after initial response.
